Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity of QL0605 vs US-Neulasta in Healthy Subjects
NCT04651036Phase 1Unknown
- Sponsor
- Qilu Pharmaceutical
- Start
- Nov 2020
- Primary completion
- Nov 2021
- Modality
- Biologic
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of pegfilgrastim-qilo in neutropenia (2 arms), sponsored by Qilu Pharmaceutical. Primary endpoint: Incidence of Anti-Drug Antibodies at 91 days. Status: unknown.
02
Drugs
pegfilgrastim-qilo
03
Conditions
neutropenia
Beyond the preview
Go deeper on NCT04651036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04651036.